CSL shares jumped 0.84% to $270.40. In comparison, the benchmark index dropped 1.18% today.
So what is happening at CSL?
How is the CSL share price performing?
Shares in the global biotech company jumped 2.15% in earlier trade to $273.95 before retreating to the current share price. For perspective, the S&P/ASX 200 Health Care Index (ASX: XHJ) also leapt more than 1% in early trade from 40,260 to 40,683 points before pulling back.
Analysts at Wilsons have recently named CSL as one of four “defensive growth” shares to buy in turbulent times.
In a memo to clients, Wilsons recommended it was “sensible” to have an above-average allocation to defensives including CSL:
Our picks are healthcare, insurance and telco.
Sectors like healthcare and consumer staples, along with utilities, have performed well against a backdrop of higher uncertainty around the US Fed’s and RBA’s hiking expectations and the impact this will have on the economy.
Share price snapshot
The CSL share price has fallen nearly 2% in the past 12 months while it has descended 7% year-to-date.
In comparison, the benchmark ASX 200 has returned less than 1% over the past year.
CSL has a market capitalisation of nearly $130 billion based on today’s share price.
The post How did the CSL share price escape the carnage today? appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of January 12th 2022
- Macquarie picks ASX 200 shares to buy in this volatile environment
- 4 ‘defensive growth’ ASX shares to buy in turbulent times: Wilsons
- The CSL share price has tumbled 8% this year. Here’s why these top brokers still have faith
- 2 strong blue chip ASX 200 shares to buy after the market selloff according to analysts
- Broker names 3 ‘champion’ ASX 200 shares to buy and hold
The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/ZdrRQ6A